Estrogen deprivation in breast cancer. Clinical, experimental, and biological aspects.
The endocrinological and clinical effects of an LH-RH agonist, Zoladex, and an antiestrogen, Nolvadex, in patients with advanced breast cancer are outlined and their potential in the therapy of nonmalignant diseases of the breast and high-risk states is briefly discussed. Additional data are presented to indicate that new antiestrogens are now available for experimental studies that, unlike tamoxifen, do not possess partial estrogen-like activity and that show favorable antitumor properties against DMBA-induced mammary tumors and MCF-7 human breast cancer cells in culture. The lack of agonistic effects of this new class of pharmacological agents now allows a state of total estrogen deprivation to be approached, a previously unobtainable clinical goal.
Nicholson
R I
RI
Breast Cancer Units, Tenovus Institute for Cancer Research, University of Wales College of Medicine, Heath Park, Cardiff.
Walker
K J
KJ
Bouzubar
N
N
Wills
R J
RJ
Gee
J M
JM
Rushmere
N K
NK
Davies
P
P
D001943:Breast Neoplasms / Q000188:drug therapy*; D002064:Buserelin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004958:Estradiol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004965:Estrogen Antagonists / Q000627:therapeutic use*; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000037:antagonists & inhibitors*; D017273:Goserelin; D006801:Humans; D008593:Menopause; D053284:Polyunsaturated Alkamides; D013629:Tamoxifen / Q000627:therapeutic use*
D004965:Estrogen Antagonists; D053284:Polyunsaturated Alkamides; D013629:Tamoxifen; D017273:Goserelin; D007987:Gonadotropin-Releasing Hormone; D004958:Estradiol; C051781:ICI 164384; D002064:Buserelin